Frazier Management LLC Cardiff Oncology, Inc. Transaction History

Frazier Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$6.65 - $10.04 $1.95 Million - $2.95 Million	-293,500 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$9.1 - $19.57 $2.5 Million - $5.38 Million	-275,000 Reduced 48.37%	293,500 $2.72 Million
Q4 2020 Feb 11, 2021	BUY	$12.02 - $24.71 $3.71 Million - $7.62 Million	308,500 Added 118.65%	568,500 $10.2 Million
Q3 2020 Nov 12, 2020	BUY	$4.25 - $14.19 $1.11 Million - $3.69 Million	260,000 New	260,000 $3.69 Million

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $170M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

Stay updated on Frazier Management LLC with notifications on news.